deltatrials
Completed PHASE1/PHASE2 NCT02562898

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma

Sponsor: Lustgarten Foundation

Conditions Metastatic Pancreatic Adenocarcinoma
Interventions Gemcitabine Ibrutinib Paclitaxel
Updated 16 times since 2017 Last updated: Apr 13, 2021 Started: Oct 12, 2015 Primary completion: Nov 15, 2019 Completion: Sep 1, 2020

A PHASE1/PHASE2 clinical study on Metastatic Pancreatic Adenocarcinoma, this trial is completed. The trial is conducted by Lustgarten Foundation and has accumulated 16 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jun 2021 — Dec 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Apr 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Nov 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jun 2018 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Aug 2017 — Apr 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lustgarten Foundation
  • Margaret Tempero
  • Stand Up To Cancer
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Portland, United States
  • • San Francisco, United States